Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional)
- Posted
- August 16, 2023
- Closed
- November 15, 2024
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.866
- Category
- Health
- Archives
- December 15, 2024
Program funding history
Awards made under Assistance Listing 93.866 across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $3.9B
- FY2026 obligated
- $3.9B
- FY2027 (to date) obligated
- $0
- Awards in window
- 10,710
Top recipients: Washington University, the, Regents of the University of Michigan, University of Southern California, The Trustees of Columbia University in the City of New York, Regents of the University of California, San Francisco, the
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the establishment ofeffective and reliable biomarkers of Alzheimers disease (AD) and AD-related dementias (ADRD) for usein therapy/medical product discovery and development, clinical trials and/or clinical practice. Specifically, this NOFO willsupport analytical and/or clinical validationof a biomarker, composite biomarker or biomarker signature, withrigor comparable with the expectations described in the Food and Drug Administration (FDA)Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways.
Who can apply
- Private institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Small businesses
- For profit organizations other than small businesses
- Public and State controlled institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Special district governments
- City or township governments
- State governments
- Independent school districts
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
The official record
Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.
View on Grants.gov Full announcement
New to federal funding? How to read an announcement · Who can apply · How grants work
Tell me when this program posts again
This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
- Early- and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline
- Research Project Cooperative Agreements in Aging and/or Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) Research
- Specialized Center Cooperative Agreements in Aging and/or Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Research
- Resource-Related Research Projects Cooperative Agreements in Aging and/or Alzheimer's Disease (AD) and Alzheimer's Disease-Related Dementias (ADRD) Research
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing